{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:25:28Z","timestamp":1781951128625,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"DOI":"10.7759\/cureus.106589","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:16:31Z","timestamp":1775571391000},"source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab-Associated Acute Liver Failure: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Lekshmi R","family":"Shenoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saquib Z","family":"Banday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Nivolumab","year":"2012","unstructured":"Nivolumab. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2012."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann L","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, et al.. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016, 60:190-209. 10.1016\/j.ejca.2016.02.025","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian SL","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al.. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012, 366:2443-54. 10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer JR","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, et al.. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012, 366:2455-65. 10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205143","article-title":"Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective","volume":"71","author":"Karamchandani DM","year":"2018","unstructured":"Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. J Clin Pathol. 2018, 71:665-71. 10.1136\/jclinpath-2018-205143","journal-title":"J Clin Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen Y","year":"2020","unstructured":"Zen Y, Chen YY, Jeng YM, Tsai HW, Yeh MM. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes. Histopathology. 2020, 76:470-80. 10.1111\/his.14000","journal-title":"Histopathology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen Y","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018, 31:965-73. 10.1038\/s41379-018-0013-y","journal-title":"Mod Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit TB","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020, 72:315-29. 10.1002\/hep.31227","journal-title":"Hepatology"},{"key":"ref9","article-title":"Identification and management of toxicities from immune checkpoint-blocking drugs","volume":"28","author":"Teply BA","year":"2014","unstructured":"Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park). 2014, 28:30-8.","journal-title":"Oncology (Williston Park)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty GJ","year":"2017","unstructured":"Doherty GJ, Duckworth AM, Davies SE, et al.. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017, 2:e000268. 10.1136\/esmoopen-2017-000268","journal-title":"ESMO Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla M","year":"2015","unstructured":"Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, Doyle LA. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015, 39:1075-84. 10.1097\/PAS.0000000000000453","journal-title":"Am J Surg Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31","author":"Kim KW","year":"2013","unstructured":"Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, Ibrahim N. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs. 2013, 31:1071-7. 10.1007\/s10637-013-9939-6","journal-title":"Invest New Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang YK","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al.. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017, 390:2461-71. 10.1016\/S0140-6736(17)31827-5","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331\u2606","volume":"32","author":"Spigel DR","year":"2021","unstructured":"Spigel DR, Vicente D, Ciuleanu TE, et al.. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331\u2606. Ann Oncol. 2021, 32:631-41. 10.1016\/j.annonc.2021.01.071","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","unstructured":"EASL clinical practice guidelines. autoimmune hepatitis. J Hepatol. 2015, 63:971-1004. 10.1016\/j.jhep.2015.06.030","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","unstructured":"EASL clinical practice guidelines. management of cholestatic liver diseases. J Hepatol. 2009, 51:237-67. 10.1016\/j.jhep.2009.04.009","journal-title":"J Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/278618-nivolumab-associated-acute-liver-failure-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:16:32Z","timestamp":1775571392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/278618-nivolumab-associated-acute-liver-failure-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.106589","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}